Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 139

1.

Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14.

Ames RS, Sarau HM, Chambers JK, Willette RN, Aiyar NV, Romanic AM, Louden CS, Foley JJ, Sauermelch CF, Coatney RW, Ao Z, Disa J, Holmes SD, Stadel JM, Martin JD, Liu WS, Glover GI, Wilson S, McNulty DE, Ellis CE, Elshourbagy NA, Shabon U, Trill JJ, Hay DW, Ohlstein EH, Bergsma DJ, Douglas SA.

Nature. 1999 Sep 16;401(6750):282-6. Erratum in: Nature 1999 Dec 23-30;402(6764):898.

PMID:
10499587
2.

Identification of urotensin II as the endogenous ligand for the orphan G-protein-coupled receptor GPR14.

Liu Q, Pong SS, Zeng Z, Zhang Q, Howard AD, Williams DL Jr, Davidoff M, Wang R, Austin CP, McDonald TP, Bai C, George SR, Evans JF, Caskey CT.

Biochem Biophys Res Commun. 1999 Dec 9;266(1):174-8.

PMID:
10581185
3.

Recent structure-activity studies of the peptide hormone urotensin-II, a potent vasoconstrictor.

Grieco P, Rovero P, Novellino E.

Curr Med Chem. 2004 Apr;11(8):969-79. Review.

PMID:
15078159
4.
5.

Human urotensin-II is a potent vasoactive peptide: pharmacological characterization in the rat, mouse, dog and primate.

Douglas SA, Ashton DJ, Sauermelch CF, Coatney RW, Ohlstein DH, Ruffolo MR, Ohlstein EH, Aiyar NV, Willette RN.

J Cardiovasc Pharmacol. 2000 Nov;36(5 Suppl 1):S163-6.

PMID:
11078367
6.

A new ligand for the urotensin II receptor.

Camarda V, Guerrini R, Kostenis E, Rizzi A, Calò G, Hattenberger A, Zucchini M, Salvadori S, Regoli D.

Br J Pharmacol. 2002 Oct;137(3):311-4.

7.

Effects of human urotensin II in isolated vessels of various species; comparison with other vasoactive agents.

Camarda V, Rizzi A, Calò G, Gendron G, Perron SI, Kostenis E, Zamboni P, Mascoli F, Regoli D.

Naunyn Schmiedebergs Arch Pharmacol. 2002 Feb;365(2):141-9. Epub 2001 Nov 20.

PMID:
11819032
8.

Co-expression of urotensin II and its receptor (GPR14) in human cardiovascular and renal tissues.

Matsushita M, Shichiri M, Imai T, Iwashina M, Tanaka H, Takasu N, Hirata Y.

J Hypertens. 2001 Dec;19(12):2185-90.

PMID:
11725162
9.

Urotensin II is the endogenous ligand of a G-protein-coupled orphan receptor, SENR (GPR14).

Mori M, Sugo T, Abe M, Shimomura Y, Kurihara M, Kitada C, Kikuchi K, Shintani Y, Kurokawa T, Onda H, Nishimura O, Fujino M.

Biochem Biophys Res Commun. 1999 Nov;265(1):123-9.

PMID:
10548501
10.

Urotensin-II receptor antagonists.

Carotenuto A, Grieco P, Rovero P, Novellino E.

Curr Med Chem. 2006;13(3):267-75. Review.

PMID:
16475936
11.

Central effects of urotensin-II following ICV administration in rats.

Gartlon J, Parker F, Harrison DC, Douglas SA, Ashmeade TE, Riley GJ, Hughes ZA, Taylor SG, Munton RP, Hagan JJ, Hunter JA, Jones DN.

Psychopharmacology (Berl). 2001 Jun;155(4):426-33.

PMID:
11441433
12.

[A vasoactive peptide: urotensin II].

Liu GQ, Zeng ZP.

Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2005 Aug;27(4):525-8. Review. Chinese.

PMID:
16178453
13.

Identification of urotensin II-related peptide as the urotensin II-immunoreactive molecule in the rat brain.

Sugo T, Murakami Y, Shimomura Y, Harada M, Abe M, Ishibashi Y, Kitada C, Miyajima N, Suzuki N, Mori M, Fujino M.

Biochem Biophys Res Commun. 2003 Oct 24;310(3):860-8.

PMID:
14550283
14.

Functional and binding characterizations of urotensin II-related peptides in human and rat urotensin II-receptor assay.

Brkovic A, Hattenberger A, Kostenis E, Klabunde T, Flohr S, Kurz M, Bourgault S, Fournier A.

J Pharmacol Exp Ther. 2003 Sep;306(3):1200-9. Epub 2003 Jun 13.

15.

Pharmacology of the urotensin-II receptor antagonist palosuran (ACT-058362; 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea sulfate salt): first demonstration of a pathophysiological role of the urotensin System.

Clozel M, Binkert C, Birker-Robaczewska M, Boukhadra C, Ding SS, Fischli W, Hess P, Mathys B, Morrison K, Müller C, Müller C, Nayler O, Qiu C, Rey M, Scherz MW, Velker J, Weller T, Xi JF, Ziltener P.

J Pharmacol Exp Ther. 2004 Oct;311(1):204-12. Epub 2004 May 14.

16.

Molecular and pharmacological characterization of genes encoding urotensin-II peptides and their cognate G-protein-coupled receptors from the mouse and monkey.

Elshourbagy NA, Douglas SA, Shabon U, Harrison S, Duddy G, Sechler JL, Ao Z, Maleeff BE, Naselsky D, Disa J, Aiyar NV.

Br J Pharmacol. 2002 May;136(1):9-22.

17.

Photolabelling the rat urotensin II/GPR14 receptor identifies a ligand-binding site in the fourth transmembrane domain.

Boucard AA, Sauvé SS, Guillemette G, Escher E, Leduc R.

Biochem J. 2003 Mar 15;370(Pt 3):829-38.

18.

The peptidic urotensin-II receptor ligand GSK248451 possesses less intrinsic activity than the low-efficacy partial agonists SB-710411 and urantide in native mammalian tissues and recombinant cell systems.

Behm DJ, Stankus G, Doe CP, Willette RN, Sarau HM, Foley JJ, Schmidt DB, Nuthulaganti P, Fornwald JA, Ames RS, Lambert DG, Calo' G, Camarda V, Aiyar NV, Douglas SA.

Br J Pharmacol. 2006 May;148(2):173-90.

20.

Supplemental Content

Support Center